10-K: AbCellera Biologics Inc. Reports Full Year 2024 Results, Advances Pipeline

AbCellera Biologics Inc. files its annual report on Form 10-K, highlighting its focus on antibody drug discovery and development, advancements in its internal programs, and strategic partnerships.

Summary

• AbCellera Biologics Inc. has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024.
• The company is focused on discovering and developing antibody-based medicines.
• AbCellera is advancing a pipeline of internal programs and strategically partnering with other companies.
• The company's first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies, with Clinical Trial Applications (CTAs) expected in Q2 2025.
• As of December 31, 2024, AbCellera has started 96 partner-initiated programs with downstream participation.
• The company estimates it has invested over $600 million in its internal capabilities.
• AbCellera had approximately $840 million in available liquidity as of December 31, 2024.
• The company expects to generate losses and negative operating cash flow in the near-to-medium term.
• Global therapeutic antibody sales approached $300 billion in 2023 and are expected to grow to over $450 billion by 2028.
• The company's voluntary turnover rate in 2024 was 4.7%.
• As of December 31, 2024, AbCellera had 596 full-time employees in Canada, the United States, and Australia.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as advancements in the pipeline and a strong liquidity position, the company is experiencing losses and expects negative cash flow in the near term. The overall outlook is cautiously optimistic.

Positives

• Advancement of internal programs ABCL635 and ABCL575 towards clinical trials.
• Significant investment in internal capabilities, estimated at over $600 million.
• Strong liquidity position with approximately $840 million available as of December 31, 2024.
• High growth potential in the therapeutic antibody market, projected to reach over $450 billion by 2028.
• Low employee turnover rate of 4.7% in 2024, indicating high employee engagement.
• Securing CAD $300 million in non-dilutive financing in May 2023 to support development and manufacturing capabilities.

Negatives

• The company has incurred losses in certain years since inception, including in 2024.
• Expected losses and negative operating cash flow in the near-to-medium term.
• Dependence on partners' success in developing and commercializing antibodies.
• The company has a limited number of product candidates, all of which are still in preclinical development.
• The market price of the company's common shares may be volatile.

Risks

• Inability to generate sufficient revenue to achieve profitability.
• Fluctuations in quarterly and annual operating results.
• Failure of partners to meet contractual obligations.
• Inability to obtain and maintain sufficient intellectual property protection.
• Potential product liability claims.
• Reliance on a limited number of suppliers for laboratory equipment and materials.
• Exposure to U.S. and foreign export controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations.
• The market price of the company's common shares may be volatile.

Future Outlook

The company expects to generate losses and negative operating cash flow in the near-to-medium term ahead of revenues generated from outlicensingand milestone payments and royalties in the longer term.

Management Comments

• The company is focused on the development of antibody-based drugs and is committed to improving the way these drugs are discovered, developed, and brought to patients.
• As business operators, we think deeply about capital allocation and strive to maximize long-term value by advancing a portfolio of antibody therapeutics both in our internal pipeline and with our strategic partners.

Industry Context

The therapeutic antibody market is one of the largest and fastest-growing classes of drugs, with global sales approaching $300 billion in 2023 and expected to grow to well over $450 billion by 2028.

Comparison to Industry Standards

• The mean peak-year sales for currently marketed monoclonal antibody drugs and monoclonal conjugate antibody drugs are estimated at over $3 billion.
• Historically, the time for antibody discovery projects to reach Phase 1 clinical trials from target selection has been estimated at approximately 5.5 years.
• On average, antibody drugs have taken between seven and ten years to reach market-authorization from the start of Phase 1 clinical trials.

Legal Proceedings

• The company is involved in patent infringement litigation with Bruker Cellular Analysis.
• The company is involved in a civil lawsuit with the Estate of John Schrader and ImmVivos Pharmaceuticals Inc.

Related Party Transactions

• The company has entered into two separate 50% joint ventures, Dayhu JV and Beedie JV, as part of the construction of new office and laboratory headquarters.
• During 2022, the Company engaged advisory services with a firm co-founded by a director of the Company.

Stakeholder Impact

• Shareholders may experience dilution from future sales and issuances of common shares.
• Employees may be affected by restructuring and reorganization activities.
• Partners may benefit from the company's enhanced discovery and development capabilities.
• Patients may benefit from the development of new antibody-based medicines.

Next Steps

• Submission of Clinical Trial Applications (CTAs) for ABCL635 and ABCL575 in Q2 2025.
• Continued investment in research and development to enhance discovery and development capabilities.
• Continued execution of internal pipeline and strategic partnerships.

Key Dates